Ziprasidone in the Psychosis Prodrome (ZIP)

Yale University

Status and phase: Completed; Phase 2

Conditions: Psychosis Prodrome

Treatments: Drug: placebo; Drug: ziprasidone

Study type: Interventional

Funder types: Other

Identifiers

NCT00635700

IIR GA1281GE

0801003386

Details and patient eligibility

About

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

Enrollment: 51 patients

Sex: All

Ages: 16 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Structured Interview for Psychosis-risk Syndromes criteria for Clinical High Risk for Psychosis
• clinically referred

Exclusion criteria

• prolonged corrected QT interval
• history of syncope

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

51 participants in 2 patient groups, including a placebo group

Ziprasidone

Experimental group

Description:

Patients will be treated with Ziprasidone for 6 months

Treatment:

Drug: ziprasidone

Placebo

Placebo Comparator group

Description:

Patients will be treated with placebo for 6 months

Treatment:

Drug: placebo